9939 Stock Overview
A clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Kintor Pharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.97 |
| 52 Week High | HK$1.98 |
| 52 Week Low | HK$0.79 |
| Beta | -0.097 |
| 1 Month Change | -11.01% |
| 3 Month Change | 5.43% |
| 1 Year Change | -37.82% |
| 3 Year Change | -97.85% |
| 5 Year Change | n/a |
| Change since IPO | -95.49% |
Recent News & Updates
Recent updates
Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?
Oct 07
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Nov 16Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Apr 28Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Dec 06Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?
Sep 01Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings
Feb 17What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)?
Dec 23
Shareholder Returns
| 9939 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.6% | -5.2% | -2.2% |
| 1Y | -37.8% | -5.3% | 18.3% |
Return vs Industry: 9939 underperformed the Hong Kong Biotechs industry which returned -5.3% over the past year.
Return vs Market: 9939 underperformed the Hong Kong Market which returned 18.3% over the past year.
Price Volatility
| 9939 volatility | |
|---|---|
| 9939 Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.7% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 9939 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9939's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 175 | Youzhi Tong | www.kintor.com.cn |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia and acne vulgaris; and Pruxelutamide (GT0918), a second-generation androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer, as well as AR-PROTAC Compound (GT20029). The company is developing Pruxelutamide (GT0918), a second generation androgen receptor (AR) for the metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours.
Kintor Pharmaceutical Limited Fundamentals Summary
| 9939 fundamental statistics | |
|---|---|
| Market cap | HK$428.64m |
| Earnings (TTM) | -HK$979.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 9939 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9939 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥41.10m |
| Gross Profit | -CN¥41.10m |
| Other Expenses | CN¥879.10m |
| Earnings | -CN¥920.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 59.8% |
How did 9939 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 09:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kintor Pharmaceutical Limited is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Zou | China International Capital Corporation Limited |
| Blanco Zhou | China Renaissance Securities |
| Bing Zhao | China Renaissance Securities |